Background
Sceletium tortuosum is a succulent plant native to southern Africa. Indigenous Khoikhoi and San peoples chewed the plant or used fermented preparations for mood elevation, social relaxation, appetite suppression, and endurance during travel. European colonists documented these uses as early as the late 17th century, with more detailed accounts appearing in 18th- and 19th-century botanical literature. Commercial interest accelerated in the early 21st century, producing standardized proprietary extracts (notably Zembrin®) and published pharmacological research on alkaloid chemistry. The plant is now sold globally as a dietary supplement, though regulatory oversight and long-term safety data remain limited relative to the scale of commercial use.
Evidence snapshot
Preclinical studies identify several Sceletium alkaloids — most notably mesembrine and mesembrenone — that inhibit serotonin reuptake in vitro and modulate intracellular signaling via PDE4 inhibition. Animal models report anxiolytic- and antidepressant-like effects. These findings establish biological plausibility but do not confirm clinical benefit in humans.
Clinical evidence is limited to small randomized and open-label trials using proprietary standardized extracts (primarily Zembrin®). These trials report reductions in anxiety reactivity and modest mood improvements in healthy adults with mild stress. Sample sizes are small (typically under 50 participants) and treatment durations short (days to weeks), leaving effect size and durability uncertain.
Short-term use at trialed doses has been generally well tolerated. Pharmacological data and case reports suggest a meaningful risk of additive serotonergic effects when combined with SSRIs, SNRIs, or MAO inhibitors. Long-term safety, effects in clinical populations, and safety in pregnancy or lactation are not established.
Bioavailability & Pharmacokinetics
Human pharmacokinetic data are sparse. Mesembrine-type alkaloids are orally active in animal models, but plasma half-lives, first-pass metabolism rates, and tissue distribution in humans have not been characterized in published studies. Standardized extracts improve dose-to-dose consistency, but the relationship between oral dose and CNS alkaloid exposure in humans remains unknown.
Populations Studied
Available clinical research has been conducted almost exclusively in healthy adults experiencing mild stress or anxiety. Data in people with clinical depression or anxiety disorders, older adults, adolescents, and individuals on chronic psychiatric medications are absent or too limited to draw conclusions. Use in pregnancy and lactation is not studied.
Long-term Safety & Tolerability
No long-term randomized controlled data exist. Short-term trial reports indicate general tolerability at 25 mg/day of standardized extract, but chronic effects on mood regulation, cognitive function, endocrine markers, and drug interactions are not established. Caution is warranted for prolonged or high-dose use.
Standardization & Product Quality
Products range from raw dried leaf to proprietary standardized extracts with specified alkaloid content. Raw plant preparations show wide batch-to-batch variability. Products that provide third-party certificate of analysis, stated mesembrine/mesembrenone content, and GMP certification are preferable for consistent and safe dosing.
Compound variations
Dried leaf / powder
Raw dried Sceletium leaf or powdered plant material; the traditional preparation form.
Common use case
Users seeking whole-plant, traditional-style preparations at lower cost.
Dosage note
Potency varies widely. If using dried leaf, starting at 50–200 mg once daily is common; standardized extracts are preferable when reproducibility matters.
Standardized extract (Zembrin®)
Proprietary extract standardized for mesembrine and mesembrenone content; used in most published clinical trials.
Common use case
Users prioritizing consistency and alignment with clinical trial dosing.
Dosage note
Human trials used 25 mg once daily. Follow product labeling and published trial protocols.
Ethanolic tincture
Alcohol-based liquid extract; potency depends on concentration ratio and plant source quality.
Common use case
Users who prefer liquid dosing and easier dose titration.
Dosage note
Concentrations vary by product. Start at the lowest recommended volume and titrate slowly based on response.
Fermented preparations
Traditionally fermented plant preparations, reported in indigenous Khoikhoi and San use. Fermentation alters alkaloid profile and flavor.
Common use case
Those interested in historically authentic preparation methods.
Dosage note
No standardized dosing exists. Alkaloid content shifts with fermentation; use small test amounts and exercise caution.
Dosage and best practices
Dosage principles
- Standardized extract (Zembrin®) as used in human trials: 25 mg once daily, delivering a defined mesembrine/mesembrenone profile. This is the most clinically anchored dose and the appropriate starting point.
- Dried leaf powder: traditional use involved gram-scale plant material, but potency varies widely across sources. If using raw leaf, starting at 50–200 mg once daily is common in modern practice; standardized extracts are preferable for reproducibility.
- Tinctures: concentrations differ by product (commonly 1:5 to 1:10 ratios). Follow manufacturer specifications, start at the lowest suggested volume, and titrate based on response. Aim to stay within alkaloid equivalence of ≤25 mg standardized extract initially.
Best practices
- Use standardized extracts with stated alkaloid content rather than raw plant preparations when seeking reproducible, predictable effects.
- Start at the lowest trialed dose. Assess response during a period when you do not need to drive or operate machinery, since sedation or activation responses vary between individuals.
- For mood or anxiety tracking, allow 2–4 weeks of daily use before drawing conclusions. For acute stress reactivity, assess within 1–3 hours of dosing.
Literature and references
Psychoactive constituents of the genus Sceletium N.E.Br. and other Mesembryanthemaceae: a review
Journal of ethnopharmacology • 1996
Review reassembling 300 years of historical records on Khoisan use of Sceletium plants in psychoactive preparations, describing how kougoed is prepared and used and the experiences of contemporary users.
Terburg D, Syal S, Rosenberger LA, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology. 2013;38(13):2708–2716.
Neuropsychopharmacology • 2013
Double-blind crossover study (n=16 healthy adults) demonstrating that a single 25 mg dose of Zembrin® reduced amygdala reactivity to threatening stimuli and attenuated amygdala–hypothalamus connectivity, supporting an anxiolytic neural mechanism.
Common questions
Is kanna legal and safe to buy?
Kanna is sold legally as an herbal supplement in many countries, including the US, UK, and Australia, but regulations and permissible health claims vary by jurisdiction. Product safety depends heavily on quality and potential interactions with medications. Check local regulations and consult a clinician if you take prescription drugs.
How fast does kanna work?
Some small studies and user reports describe changes in anxiety or stress reactivity within 1–3 hours of a single dose. Mood effects in clinical trials were assessed over days to weeks. Individual response time varies considerably.
Can I take kanna with my SSRI?
Combining kanna with SSRIs or other serotonergic medications adds serotonergic activity and carries a theoretical risk of serotonin syndrome. Avoid this combination without direct medical supervision.
Which form is best — dried leaf or standardized extract?
Standardized extracts with listed alkaloid content offer more consistent dosing and align with the preparations studied in clinical trials. Raw leaf preparations vary widely in potency and are less predictable.
Is kanna addictive?
Published literature and traditional use reports have not identified a clear dependence pattern. However, data are insufficient to fully characterize misuse potential, particularly with frequent high-dose use.